Abstract:Mutant isocitrate dehydrogenase 1 (mIDH1) is a common driving factor in acute myeloid leukemia (AML), with the R132 mutation accounting for a high proportion. The U.S. Food and Drug Administration (FDA) approved Ivosidenib, a molecular entity that targets IDH1 with R132 mutations, as a promising therapeutic option for AML with mIDH1 in 2018. It was of concern that the occurrence of disease resistance or recurrence, attributed to the IDH1 R132C/S280F second site mutation, was observed in certain patients treated with Ivosidenib within the same year. Furthermore, it should be noted that most mIDH1 inhibitors demonstrated limited efficacy against mutations at this specific site. Therefore, there is an urgent need to investigate novel inhibitors targeting mIDH1 for combating resistance caused by IDH1 R132C/S280F mutations in AML. This study aimed to identify novel mIDH1 R132C/S280F inhibitors through an integrated strategy of combining virtual screening and dynamics simulations. First, 2000 hits were obtained through structure-based virtual screening of the COCONUT database, and hits with better scores than −10.67 kcal/mol were obtained through molecular docking. A total of 12 potential small molecule inhibitors were identified through pharmacophore modeling screening and Prime MM-GBSA. Dynamics simulations were used to study the binding modes between the positive drug and the first three hits and IDH1 carrying the R132C/S280F mutation. RMSD showed that the four dynamics simulation systems remained stable, and RMSF and Rg showed that the screened molecules have similar local flexibility and tightness to the positive drug. Finally, the lowest energy conformation, hydrogen bond analysis, and free energy decomposition results indicate that in the entire system the key residues LEU120, TRP124, TRP267, and VAL281 mainly contribute van der Waals forces to the interaction, while the key residues VAL276 and CYS379 mainly contribute electrostatic forces.

Structure-based Design, Synthesis and Bioactivity Evaluation of Macrocyclic Inhibitors of Mutant Isocitrate Dehydrogenase 2 (IDH2) Displaying Activity in Acute Myeloid Leukemia Cells.

Structure-Based Drug Design of Novel Triaminotriazine Derivatives As Orally Bioavailable IDH2R140Q Inhibitors with High Selectivity and Reduced Herg Inhibitory Activity for the Treatment of Acute Myeloid Leukemia.

Discovery and Optimization of 2 H -1λ 2 -Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer

Identification of New IDH2R140Q Inhibitors by Discriminatory Analysis‐based Molecular Docking and Biological Evaluation

Molecular Modeling Studies to Discover Novel Midh2 Inhibitors with High Selectivity for the Primary and Secondary Mutants

Design, Synthesis and Biological Activity of 3-Pyrazine-2-yl-oxazolidin-2-ones As Novel, Potent and Selective Inhibitors of Mutant Isocitrate Dehydrogenase 1.

Design and Synthesis of Novel 2-Arylbenzimidazoles As Selective Mutant Isocitrate Dehydrogenase 2 R140Q Inhibitors.

Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

3D-QSAR and Docking Studies on 1-Hydroxypyridin-2-one Compounds As Mutant Isocitrate Dehydrogenase 1 Inhibitors

3D-QSAR, Molecular Docking and Molecular Dynamics Simulations Study of 3-Pyrimidin-4-yl-oxazolidin-2-one Derivatives to Explore the Structure Requirements of Mutant IDH1 Inhibitors

3D-QSAR, Scaffold Hopping, Virtual Screening, and Molecular Dynamics Simulations of Pyridin-2-one as mIDH1 Inhibitors

Comprehensive Exploration of Isocitrate Dehydrogenase (IDH) Mutations: Tumorigenesis, Drug Discovery, and Covalent Inhibitor Advances

Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations

Exploration of Natural Products for Targeting IDH1/2 Mutations in Acute Myeloid Leukemia through Ligand-Based Pharmacophore Screening, Docking, ADME-T and Molecular Dynamic Simulation Approaches

Identification of New Inhibitors of Mutant Isocitrate Dehydrogenase 2 through Molecular Similarity-based Virtual Screening

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

Computational study on novel natural compound inhibitor targeting IDH1_R132H

Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening

Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.

Discovery of a novel class of pyridine derivatives that selectively inhibits mutant isocitrate dehydrogenase 2.